Granulocyte and granulocyte-macrophage colony-stimulating factors

The Lancet

Volumn 342, Issue 8864, 1993, Pages 153-157

  Steward, W P ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROLINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

BONE PAIN; CANCER CHEMOTHERAPY; GRANULOCYTE; HEMATOPOIESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW;

GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMAN; NEUTROPENIA;

EID: 0027174897     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(93)91350-U     Document Type: Article

References (31)

1. Recombinant human granulocyte colony-stimulating factor: effects on hematopoiesis in normal and cyclophosphamide-treated primates
2. The molecular biology and functions of the granulocyte-macrophage colony stimulating factors
3. Granulocyte-macrophage colony-stimulating factor induces change in cellular adhesion molecule expression and adhesion to endothelium: in vitro and in vivo studies in man
4. Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy
5. Treatment of chemotherapy induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy
6. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) given as daily short infusions-a phase I dose-toxicity study
7. Effects of bacterially- synthesised recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy
8. Clonal analysis of progenitor cell commitment to granulocyte or macrophage formation
9. Dose escalation study of recombinant human granulocyte colony-stimulating factor (KRN8601) in patients with advanced malignancy
10. Pharmackinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay
11. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer
12. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to transitional cell carcinoma of the urothelium
13. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression
14. Effect of recombinant granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer
15. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
16. A double-blind placebo controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma
17. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation
18. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy, and autologous bone marrow transplantation.
19. Granulocyte-macrophage colony-stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer
20. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer
21. Granulocyte-macrophage colony-stimulating factor expands the circulating haemopoietic progenitor cell compartment in man
22. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
23. Treatment for cyclic neutropenia with granulocyte colony-stimulating factor
24. Granulocyte-macrophage colony-stimulating factor (GM-CSF) for aplastic anemia (AA): preliminary results of a multi-centre randomised controlled trial
25. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine
26. Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodefficiency virus infection
27. Differential effects of G-CSF and GM-CSF in acquired chronic neutropenia
28. Characterisation of the clinical effects after the first dose of bacterially synthesised recombinant human granulocyte-macrophage colony-stimulating factor
29. GM-CSF decreased duration of cytopenia and hospitalization, and in-hospital costs in patients with Hodgkin's disease treated with high-dose chemotherapy and autologous bone marrow transfusion (ABMT)
30. The control of growth and differentiation in normal and leukemic blood cells